Cantor Fitzgerald Downgrades Longboard Pharmaceuticals to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has downgraded Longboard Pharmaceuticals from Overweight to Neutral, indicating a change in the analyst's outlook on the company's stock.
October 14, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has downgraded Longboard Pharmaceuticals from Overweight to Neutral, suggesting a less optimistic view on the stock.
The downgrade from Overweight to Neutral by a reputable analyst like Josh Schimmer at Cantor Fitzgerald typically signals a less favorable outlook on the stock, which can lead to a short-term negative impact on the stock price as investors may adjust their positions based on this new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100